PRESS RELEASE
2 October 2026

Foley Hoag Advises Axogen On $200M Acquisition Of BioCircuit Technologies

FH
Foley Hoag LLP

Contributor

Foley Hoag provides innovative, strategic legal services to public, private and government clients. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse experiences of our lawyers contribute to the exceptional senior-level service we deliver to clients.
Foley Hoag advised Axogen, Inc., a global leader in peripheral nerve function restoration, in its $200 million acquisition of BioCircuit Technologies, Inc., developer of NerveTape™, the first FDA-cleared device for sutureless peripheral nerve repair
United States

=

Foley Hoag advised Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing surgical solutions for the restoration of peripheral nerve function, in its $200 million acquisition of BioCircuit Technologies, Inc., a privately held medical device company and developer of NerveTape™, the first FDA-cleared device for sutureless peripheral nerve repair.

The acquisition expands Axogen's portfolio of nerve repair technologies and adds NerveTape™, an innovative solution designed to simplify and enhance peripheral nerve repair procedures.

The Foley Hoag team was led by Mark Haddad and included Nitzan Fisher Conforti, Lee Ramati, Ariel Chen, Hannah Melville, Earl Mellott, Alex Levay, Barbara Klepper, John Harre, Janine Ladislaw, and Alison Anderson.

Contributor

Foley Hoag provides innovative, strategic legal services to public, private and government clients. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse experiences of our lawyers contribute to the exceptional senior-level service we deliver to clients.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More